Nicholas C. Richardson

United States Food and Drug Administration

Also affiliated with University of Indianapolis, Indiana University – Purdue University Indianapolis

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective”.

Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3579

N/A

0DataRank · unranked

11 citations

Maryam Sarraf Yazdy, Yvette L. Kasamon, Rachel Ershler, Emily Y. Jen, Bindu Kanapuru +7 more

FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1729

N/A

0DataRank · unranked

7 citations

Yvette L. Kasamon, Wenjuan Gu, Lisa R. Rodriguez, Susan Jin, Vishal Bhatnagar +5 more

FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1035

N/A

0DataRank · unranked

5 citations

Upendra Mahat, Nicholas C. Richardson, Million A. Tegenge, Qianmiao Gao, Marc R. Theoret +2 more